Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07040332

Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis

This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Allergic Bronchopulmonary Aspergillosis (ABPA) Aspergillosis Aspergillosis, Allergic Bronchopulmonary Bacterial Infections and Mycoses Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Infections Lung Diseases Lung Diseases, Fungal Mycoses Pulmonary Aspergillosis Respiratory Hypersensitivity Respiratory Tract Diseases Respiratory Tract Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China

Jinan, Shandong, 250014, China

Location status: Recruiting

Location contact

Qian Qi, Dr.

CONTACT

[email protected]

+86 13706380314

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meets the diagnostic criteria for allergic bronchopulmonary aspergillosis.
  • Meets the diagnostic criteria for fungal-sensitized asthma.

Exclusion criteria

  • Human immunodeficiency virus infection.
  • Malignant tumor.
  • Blood system disease.
  • autoimmune system disease.
  • History of pulmonary tuberculosis.
  • Patients with a history of smoking or still smoking.
  • Invasive pulmonary fungal disease.
  • Contraindications electronic bronchoscopy

Treatment and study plan

Primary outcomes

  1. Total serum IgE

    Time frame: Up to 12 months

Secondary outcomes

  1. Aspergillus-specific IgE

    Time frame: Up to 12 months

  2. Aspergillus-specific IgG

    Time frame: Up to 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Qian Qi, Prof.

CONTACT

[email protected]

+86 13706380314

Sponsors and collaborators

Lead sponsor

Qianfoshan Hospital

Other

Collaborators

  • Fudan University
  • Guizhou Provincial People's Hospital
  • Qilu Hospital of Shandong University
  • Shanghai Pulmonary Hospital, Shanghai, China
  • The First Hospital of Jilin University

Registry information

Important dates

Study start
2025
Primary completion
2027
Study completion
2029
First posted
Jun 27, 2025
Registry last updated
Jul 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.